Cancer Genetics and Genetic Testing – It’s Not All in the Family - LIVE
This live webinar has already taken place.
You can watch a recording of the webinar in our video library.
Take any of our Self-Paced, Online Courses and complete an assessment and an evaluation to earn free CE credit*.
*In most cases, Accreditation prohibit the repeated use of the same educational activity (Live Webinar or Self-Paced, Online Course but not both) as it relates to satisfying CE requirements to maintain licensure. Attendees are also required to achieve a score of 80% or better on an assessment for the Self-Paced, Online Course to receive CE credit. Please contact your individual accreditation agencies for more details.
Genetic sequencing technologies are increasingly applied in the oncology setting for a variety of purposes. Genetic testing of tumor specimens can help clarify a diagnosis and inform targeted therapies. Circulating tumor DNA can be detected in blood samples and can also guide therapy as well as monitoring for response to treatment or recurrence. Five to ten percent of cancers are the result of an underlying hereditary syndrome. Dedicated germline (i.e. hereditary) genetic tests are required to identify these syndromes, but other genetic tests may provide clues about the chance of a hereditary syndrome. Inappropriate use of other types of genetic testing to assess germline risk can result in harm to patients. We propose to provide education about various oncology genetic tests and their uses, with an emphasis on what those tests may (or may not) tell us about underlying hereditary risk. We will illustrate this with case examples, including a recent case referred to us who underwent prophylactic surgeries after being told she had BRCA1/2 associated hereditary breast and ovarian cancer syndrome following incorrect ordering of a test that did not address germline risk and misinterpretation of the results.
These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, registered nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, allied health personnel, and others who are interested in care for patients and survivors in North Carolina.
- Differentiate between germline, tumor and cell free DNA test products and their application in cancer care.
- Identify features of somatic test results that suggest need for hereditary cancer testing.
- Recognize risks to patients when errors in genetic test ordering or interpretation occur.
Please feel free to share the flyer and/or this webpage.
Taking the Course
To continue, click the button Take Course.
If you do not see the button, please ensure that you are logged in. If you are logged in and still don't see the button, please contact us at firstname.lastname@example.org or (919) 445–1000.
Kate Foreman, MS, CGC
Clinical Assistant Professor & Genetic Counselor
Presenter Disclosure Information
Kate Foreman, MS, CGC, has no relevant financial relationships with commercial interests as defined by the ACCME.
The Greensboro Area Health Education Center is approved as a provider of nursing continuing professional development by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approved by the UNC Eshelman School of Pharmacy for ACPE.
Approved by the American Society of Radiologic Technologists (ASRT).
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Tech
- 1.00 ASRT
- 1.00 CTR
- 1.00 NCPD/CNE
- 1.00 Participation